A natural seaweed derived mineral supplement (Aquamin F) for knee osteoarthritis: a randomised, placebo controlled pilot study

Joy L Frestedt, Michael A Kuskowski, John L Zenk, Joy L Frestedt, Michael A Kuskowski, John L Zenk

Abstract

Background: Osteoarthritis (OA) is a slowly destructive process that may be influenced by a nutritional mineral balance in the body.

Methods: This small, double blind, placebo controlled pilot study investigated the impact of treatment with a natural multi-mineral supplement from seaweed (Aquamin) on 6 minute walking distance (6 MWD), range of motion (ROM), and pain and joint mobility measured by the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in subjects with moderate to severe OA of the knee during gradual withdrawal of non-steroidal anti-inflammatory drugs (NSAIDs) that were being used daily for pain management. Subjects (n = 29) with moderate to severe OA of the knee were randomised to receive either Aquamin (2400 mg/d) or Placebo for up to 12 weeks.

Results: Of the 29 subjects initially randomized, only 22 subjects proceeded to treatment due to 7 subjects not meeting study selection criteria at baseline. Fourteen subjects completed the study and an ITT analysis (n = 22) of the data showed no significant differences in WOMAC scores however, the data did reveal significant improvements in passive and active extension ROM (0.83 degrees +/- 1.54 vs. -1.54 degrees +/- 2.43; difference, 5.2 degrees +/- 2.2, p = 0.028) and 6 MWD (150 +/- 48 ft vs. 12.5 +/- 31.5 ft; difference, 136 +/- 57 ft, p = 0.03) in the Aquamin group compared to the placebo group; respectively, following a 50% reduction in NSAID use. The treatments were well tolerated and the adverse event profiles were not significantly different between the groups.

Conclusion: This small preliminary study suggests Aquamin may increase range of motion and walking distances in subjects with OA of the knee and may allow partial withdrawal of NSAIDs over 12 weeks of treatment. Additional research is needed to confirm these preliminary observations.

Trial registration: NCT00755482.

Figures

Figure 1
Figure 1
Trial flow chart.
Figure 2
Figure 2
Active and passive ROM over time. Change (Degrees) in ROM over 12 weeks of treatment.
Figure 3
Figure 3
Walking distance over time. Change in distance (Feet) walked over 12 weeks of treatment.

References

    1. Elders MJ. The increasing impact of arthritis on public health. J Rheumatol Suppl. 2000;60:6–8.
    1. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–1091. doi: 10.1056/NEJMoa050330.
    1. Ray WA, Griffin MR, Stein CM. Cardiovascular toxicity of valdecoxib. N Engl J Med. 2004;351:2767. doi: 10.1056/NEJMc045711.
    1. da Camara CC, Dowless GV. Glucosamine sulfate for osteoarthritis. Ann Pharmacother. 1998;32:580–587. doi: 10.1345/aph.17214.
    1. Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, Ledda A, Di Renzo A, Stuard S, Dugall M, et al. Treatment of osteoarthritis with Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytother Res. 2008;22:518–523. doi: 10.1002/ptr.2376.
    1. Poolsup N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother. 2005;39:1080–1087. doi: 10.1345/aph.1E576.
    1. Shakibaei M, Kociok K, Forster C, Vormann J, Gunther T, Stahlmann R, Merker HJ. Comparative evaluation of ultrastructural changes in articular cartilage of ofloxacin-treated and magnesium-deficient immature rats. Toxicol Pathol. 1996;24:580–587.
    1. Gaby AR. Natural treatments for osteoarthritis. Altern Med Rev. 1999;4:330–341.
    1. Jensen NH. [Reduced pain from osteoarthritis in hip joint or knee joint during treatment with calcium ascorbate. A randomized, placebo-controlled cross-over trial in general practice] Ugeskr Laeger. 2003;165:2563–2566.
    1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in subjects with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–1840.
    1. Frestedt JL, Walsh M, Kuskowski MA, Zenk JL. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. Nutr J. 2008;7:9. doi: 10.1186/1475-2891-7-9.
    1. Zenk JL, et al. The effects of milk protein concentrate on the symptoms of osteoarthritis in adults: an exploratory, randomised, double-blind, placebo-controlled trial. Curr Ther Res. 2002;63:430–442. doi: 10.1016/S0011-393X(02)80049-2.
    1. Altman R, Asch E, Bloch G, et al. The American College of Rheumatology Criteria for the Classification and Reporting of Osteoarthritis of the Knee. Arthritis Rheum. 1986;29:1039–1049. doi: 10.1002/art.1780290816.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever